- $10.72bn
- $9.81bn
- $396.29m
Annual balance sheet for Astera Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Short Term Investments | |||
Cash and Short Term Investments | 163 | 149 | 914 |
Net Total Accounts Receivable | |||
Net Total Receivables | 10.7 | 8.34 | 38.8 |
Total Inventory | |||
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 206 | 186 | 1,013 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 5.29 | 7.58 | 38.6 |
Other Long Term Assets | |||
Total Assets | 212 | 196 | 1,055 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 40.1 | 35.1 | 86.5 |
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 41.9 | 38.9 | 89.7 |
Redeemable Preferred Stock | |||
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Unrealized Gain / Loss | |||
Total Equity | 170 | 157 | 965 |
Total Liabilities & Shareholders' Equity | 212 | 196 | 1,055 |
Total Common Shares Outstanding |